Business Context and Reporting Period
This Form 8-K filing by NRC Health covers the date of April 27, 2026. The report details amendments to previously granted equity awards for three senior executives: Trent Green (CEO), Helen Hrdy (COO), and Andrew Monich (Chief Corporate Development Officer). The changes were made to resolve tax uncertainties regarding vesting dates and to align executive interests with stockholders as originally intended.
Key Financial Metrics and Impact
The filing does not provide standard operating metrics such as revenue, profit, cash flow, or debt levels. However, it discloses specific financial impacts related to the executive compensation amendments:
- Total Expected Expense: Approximately $9.4 million to be recognized in the second quarter of 2026.
- Non-Cash Equity Expense: Approximately $6.5 million representing accelerated equity compensation.
- Cash Bonus Expense: Approximately $2.9 million paid to cover estimated tax liabilities for the executives.
- Individual Bonuses: Approximately $1.9 million for Mr. Green and $0.5 million each for Ms. Hrdy and Mr. Monich.
Material Changes and Unusual Items
The primary material change is the acceleration of equity compensation expense. Originally, the $6.5 million in equity expense was to be recognized ratably through the second quarter of 2028. Due to the amendment eliminating the company's repurchase right, this expense is now fully recognized in Q2 2026. Additionally, the filing notes that the Company's effective tax rate for the second quarter and the remainder of 2026 is expected to be negatively impacted because these amounts are non-deductible.
Guidance, Outlook, and Risks
Management commentary indicates that the amendments were necessary to achieve the intended alignment with stockholders and to place executives in the position originally envisioned when the grants were made in 2025. The filing includes standard forward-looking statement disclaimers, noting that actual results may differ from expectations due to significant risks and uncertainties. No specific operational guidance or revenue outlook is provided in this document.
Investor Verification Checklist
- Verify the exact timing of the $9.4 million expense recognition in the upcoming Q2 2026 earnings report.
- Confirm the impact of the non-deductible expenses on the Company's effective tax rate for 2026.
- Review the amended award agreements to ensure the repurchase rights have been fully eliminated as stated.
- Assess whether the cash outflow of $2.9 million affects the Company's current liquidity position.